Jenburkt (JENBURPH) | Stock Overview & Key Data
Jenburkt Performance Comparison
Stock Range
Today's Range
Low: ₹1,052.55
High: ₹1,082.70
on October 3, 2025
52 Week Range
Low: ₹936.70
High: ₹1,410.00
on February 28, 2025
on July 8, 2025
All-Time High: ₹1,410.00 on July 8, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR4.9B
EPS
73.46
P/E Ratio (TTM)
14.89
Forward P/E
31.38
P/B Ratio
2.81
PEG Ratio
2.91
Div. Yield
2.48%
ROE
18.66%
Beta
0.381
Debt to Equity
2.27
Financial Highlights
Profitability
Gross Margin
81.65%
Operating Margin
23.18%
Profit Margin
20.97%
Returns and Earnings
Return on Assets (TTM)
16.34%
Return on Equity (TTM)
18.66%
EBITDA
INR473.6M
Net Income (TTM)
INR324.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR350.49
Quarterly Revenue Growth (YoY)
9.20%
Quarterly Earnings Growth (YoY)
5.10%
Dividend Information
Last 12-Month Dividend
₹33.30
Current Dividend Yield
2.48%
3-Year Average Dividend Yield
1.83%
3-Year Average Annual Dividend
₹19.90
3-Year Total Dividends
₹59.70
Ex-Dividend Date
July 11, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Jenburkt JENBURPH | 4.87B Small-cap | -1.85% | -5.15% | -20.20% | 5.78% | -11.50% | 8.77% | 96.74% | 188.92% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 0.56% | 4.66% | -1.86% | -3.66% | -13.43% | -14.34% | 71.30% | 219.01% |
| Divi's Laboratories DIVISLAB | 1.57T Large-cap | -4.58% | -6.29% | -16.72% | 2.89% | -5.98% | 5.24% | 52.85% | 79.00% |
| Suven Life Sciences SUVEN | 48.20B Small-cap | -6.65% | -0.56% | -18.38% | 69.66% | 61.86% | 45.66% | 184.80% | 304.79% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Aarti Drugs AARTIDRUGS | 44.55B Small-cap | -5.64% | 3.08% | 3.92% | 42.25% | 7.15% | -5.48% | -1.60% | -50.42% |
Ownership & Short Interest
Insider Ownership
73.17%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
2K
Average 90-Day Volume
1K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is JENBURPH's 52-week high and low?
- In the last 52 weeks, Jenburkt reached a high of ₹1,410.00 (on July 8, 2025) and a low of ₹936.70 (on February 28, 2025).
- What is the market cap and P/E ratio for JENBURPH?
- Curious about Jenburkt's size and valuation? Its market capitalization stands at 4.87B. When it comes to valuation, the P/E ratio (trailing twelve months) is 14.89, and the forward P/E (looking ahead) is 31.38.
- Does JENBURPH pay dividends? If so, what's the yield?
- Yes, Jenburkt is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 2.48%, and the company has paid an average of ₹19.90 per share annually over the past 3 years.
- Who are Jenburkt's main competitors or similar companies to consider before investing?
When looking at Jenburkt, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.34% 71.30% Divi's Laboratories
DIVISLAB1.57T Healthcare Drug Manufacturers - Specialty & Generic 5.24% 52.85% Suven Life Sciences
SUVEN48.20B Healthcare Drug Manufacturers - Specialty & Generic 45.66% 184.80% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Aarti Drugs
AARTIDRUGS44.55B Healthcare Drug Manufacturers - Specialty & Generic -5.48% -1.60% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Jenburkt Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Jenburkt's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 18.66%, the Debt to Equity ratio from the most recent quarter is 2.27, and its Gross Profit Margin stands at 81.65%.
- What is the recent revenue and earnings growth for JENBURPH?
- Looking at Jenburkt's growth, its revenue over the trailing twelve months (TTM) was INR2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.20%, and quarterly earnings saw a YoY growth of 5.10%.
- How much of JENBURPH stock is held by insiders and institutions?
- Wondering who owns Jenburkt stock? Company insiders (like executives and directors) hold about 73.17% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.